Home
Company
Archives for Aral Egilmez

News & Events

Here you’ll find details on happenings within our company, industry news, and updates on our innovative line of products.

Therapyx receives FDA Orphan Drug Designation for FAPXIL, a first-in-class immune therapy for the treatment of Familial Adenomatous Polyposis
09.15.233 min read
The National Institutes of Health awards a new grant in the amount of $3 million to Therapyx to continue the development of GneX12, a first-in-class immune therapy to induce protection against reinfection with Neisseria Gonorrhoeae
09.12.233 min read
The National Institutes of Health awards a new grant in the amount of $3 million to Therapyx to continue its development of FAPXIL, a first-in-class oral immune therapy for Familial Adenomatous Polyposis
09.07.233 min read
Updated NIH FCOI Policy
03.04.2115 min read
Therapyx, Inc. receives an NIH SBIR Phase IIb grant in the amount of $2.8 million to advance its mucosal immunization platform
08.11.204 min read
The National Institutes of Health Awards a new grant in the amount of $2.91 million to Therapyx
05.13.203 min read

1
2

footer bubble icon

Let's Talk

Interested? Let’s change the future of pharmaceuticals together.